Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy
February 22, 2024 08:30 ET
|
Avenue Therapeutics
MIAMI, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of...
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
February 14, 2024 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
Epilepsy Market to Observe Stunning Growth by 2032, Predicts DelveInsight | Key Players in the Market - Xenon Pharmaceuticals, Aquestive Therapeutics, Takeda, Ovid Therapeutics, Eisai, Biohaven Pharmaceuticals, UCB Pharma
February 08, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Epilepsy Market to Observe Stunning Growth by 2032, Predicts DelveInsight | Key Players in the Market - Xenon Pharmaceuticals, Aquestive...
Neurona Therapeutics Raises $120M to Advance Groundbreaking Pipeline of Regenerative Cell Therapy Candidates for Chronic Neurological Disorders
February 08, 2024 08:00 ET
|
Neurona Therapeutics
$120M financing will support advancement of ground-breaking regenerative cell therapies for chronic CNS disorders
Epilepsy Therapeutics market is projected to grow at a CAGR of 8.1% by 2034: Visiongain
February 02, 2024 04:00 ET
|
Visiongain Reports Ltd
Visiongain has published a new report entitled Epilepsy Therapeutics Market Report 2024-2034: Forecasts by Drug Class (First Generation Drugs, Second Generation Drugs, Third Generation Drugs), by...
APAC Epilepsy Therapeutic Market Poised for Growth, Set to Expand by USD 449.35 Mn through 2023-2028
January 31, 2024 11:13 ET
|
Research and Markets
Dublin, Jan. 31, 2024 (GLOBE NEWSWIRE) -- The "Epilepsy Therapeutic Market in APAC 2024-2028" report has been added to ResearchAndMarkets.com's offering. The epilepsy therapeutic market in the...
Urgent call for timely, affordable access to new life-changing epilepsy treatments in Canada
January 10, 2024 07:00 ET
|
Canadian Epilepsy Alliance
Calgary, AB, Jan. 10, 2024 (GLOBE NEWSWIRE) -- The Canadian Epilepsy Alliance, along with physicians, patients and their families are calling on provincial Health Ministers to address an unmet need...
Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio
January 08, 2024 08:00 ET
|
Praxis Precision Medicines, Inc.
Positive preliminary analysis of 15 mg cohort in the PRAX-628 study in epilepsy patients with Photo-Paroxysmal Response (PPR) exceeds expectations; topline results expected in 1Q 2024 after completion...
Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
January 04, 2024 16:49 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) announced today that it has commenced an underwritten public...
Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE®
January 04, 2024 12:00 ET
|
CROSSJECT
Press Release Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE® Crossject expanding market access activities in preparation for filing for marketing authorization ...